E
Neonc Technologies Holdings, Inc. NTHI
$8.86 $0.516.11% NASDAQ
Recommendation
Prev Close
$8.86
Volume
27,494
Avg Vol (90D)
179,122
Market Cap
$169.75M
Dividend & Yield
--
52-Week Range
$3.20 - $25.00
P/E (TTM)
--
EPS (TTM)
-$2.21
My Lists My Alerts
Access our Premium Ratings
Get Access
Rating
Reward
Risk
Rating Factors
Growth Index
Efficiency Index
Solvency Index
Total Return Index
Volatility Index
Dividend Index
Headlines
NeOnc Technologies Announces $50M Partnership with Quazar
10/10/2025 - TipRanks Financial Blog
NeOnc Technologies' Subsidiary, NuroMENA, Signs Master Services Agreement with M42's IROS and Expands Board of Directors
10/9/2025 - Globe Newswire
NeOnc Technologies and Quazar Investment Set to Close $50 Million Strategic Partnership by October 23rd Following Final UAE Tax Approvals
10/6/2025 - Globe Newswire
NeOnc Technologies Appoints Dr. David M. Ashley, Director of The Preston Robert Tisch Brain Tumor Center at Duke, to Scientific Advisory Board
10/2/2025 - Globe Newswire
NeOnc Technologies Welcomes Dr. Alexandra M. Miller, Chief of Neuro-Oncology and Co-Director of the Brain and Spine Tumor Center at NYU Langone Health's Perlmutter Cancer Center, to Its Scientific Advisory Board
10/1/2025 - Globe Newswire
NeOnc Technologies Appoints Renowned Neuro-Oncologist Dr. Henry S. Friedman to Scientific Advisory Board
9/29/2025 - Globe Newswire
NeOnc Technologies to Showcase Progress on Addressing Brain Cancer to 63 Million TV Households on Health Uncensored with Dr. Drew on the Lifetime Network on September 25, premiering nationwide at 8:00 a.m. ET/PT
9/22/2025 - Globe Newswire
NeOnc Technologies Advances to Phase II Brain Cancer Trial
9/11/2025 - TipRanks Financial Blog
Blue Gold Appoints Quazar's Sameer Salgar to Advisory Board to Establish UAE Ties and Guide Digital Gold Strategy
9/10/2025 - Globe Newswire
NeOnc Technologies Receives FDA Authorization to Proceed with Phase II Clinical Trial of NEO212 A First-in-Class Oral Chemical Conjugated Chemotherapy Candidate for Brain Cancer
9/10/2025 - Globe Newswire
NeOnc Technologies Closes Strategic Acquisition of Advanced AI and 3D Bioprinting IP, Appointing World-Renowned Scientist Dr. Ishwar K. Puri to its Board
8/25/2025 - Globe Newswire
NeOnc Completes Acquisition and Board Reshuffle
8/22/2025 - TipRanks Financial Blog
NeOnc Technologies Holdings Reports Second Quarter 2025 Results and Provides Operational Update ...
8/19/2025 - GuruFocus
NeOnc Technologies Holdings Reports Second Quarter 2025 Results and Provides Operational Update
8/19/2025 - GuruFocus
NeOnc Technologies Holdings Reports Second Quarter 2025 Results and Provides Operational Update
8/19/2025 - Globe Newswire
NeOnc Technologies Expands with NuroMENA Holdings Incorporation
8/13/2025 - TipRanks Financial Blog
NeOnc Technologies Finalizes All Contingencies for $50 Million Strategic Partnership with Quazar Investment as NuroMENA Holdings Receives ADGM Incorporation
8/11/2025 - Globe Newswire
NeOnc Technologies Awarded $2.5 Million in NIH STTR Grants to Advance NEO212 in Gliomas and Leukemia
8/7/2025 - Globe Newswire
NeOnc Technologies Featured on 's Podcast Trader Talk: AI and Biotech Take on Brain Cancer
8/4/2025 - Globe Newswire
NeOnc Technologies Acquires AI and Quantum IP Portfolio
8/1/2025 - TipRanks Financial Blog
NeOnc Technologies Signs Definitive Agreement to Acquire AI, 3D, and Quantum Modeling IP Portfolio from Dr. Ishwar K. Puri; Appoints Him to Board of Directors
7/30/2025 - Globe Newswire
NeOnc Technologies Signs Definitive Agreement for $50 Million Strategic Partnership with Quazar Investment
7/29/2025 - Globe Newswire
NeOnc Technologies to Participate at the BTIG Virtual Biotechnology Conference
7/28/2025 - Globe Newswire
NeOnc Technologies Signs Sub-License Agreement with NuroCure
7/25/2025 - TipRanks Financial Blog
CORRECTING and REPLACING - NeOnc Technologies Holdings, Inc. NTHI Stock News
7/23/2025 - GuruFocus
Income Statement
Total Revenue (TTM)
--
EBITDA (TTM)
--
EBIT (TTM)
--
Net Income (TTM)
--
Balance Sheet
Total Assets (Q)
$2.99M
Total Debt (Q)
$395.50K
Total Liabilities (Q)
$14.80M
Book Value Per Share (Q)
-$0.621
Cash Flow
Cash from Operations (TTM)
--
Cash from Investing (TTM)
--
Cash from Financing (TTM)
--
Net Change in Cash (TTM)
--
Filings
Filing Date
Monday, August 18, 2025
Period Date
Monday, June 30, 2025
Next Filing
Beginning of January (est)
Price History
Loading...
Beta
--
7-Day Total Return
-15.46%
30-Day Total Return
-11.13%
60-Day Total Return
86.53%
90-Day Total Return
86.13%
Year to Date Total Return
-26.84%
1-Year Total Return
--
2-Year Total Return
--
3-Year Total Return
--
5-Year Total Return
--
52-week Low
Jul 02, 2025 - $3.20
52-week High
Mar 26, 2025 - $25.00
Valuation
Market Cap
$169.75M - Micro Cap
Enterprise Value
$170.02M
Price/Sales (TTM)
2,858.06
Price/Book (Q)
-14.27
Dividends and Shares
Shares Outstanding
19.03
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
www.neonc.com
Phone Number
310-663-7831
Address
23975 Park Sorrento
Calabasas, CA 91302
Country
United States
Year Founded
2005
Business Description
Sector
Health Care
Industry
Pharmaceuticals, Biotechnology and Life Sciences
NeOnc Technologies Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for intracranial malignancies. Its lead product candidates include NEO100, a... more
NASDAQ 10/24/2025 4:00PM Eastern Quotes delayed